IMWG consensus on risk stratification in multiple myeloma

#	Paper	IF	Citations
450	[Analytical performances of SPAPLUS❑ turbidimeter for the dosage of immunoglobulins and beta-2 microglobulin in serum]. **2014**, 72, 423-34		
449	Multiple myeloma: optimal management and long-term disease control. **2014**, 121		
448	Implications of heterogeneity in multiple myeloma. *BioMed Research International*, **2014**, 2014, 232546	3	30
447	Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. *BioMed Research International*, **2014**, 2014, 893243	3	11
446	MicroRNA: important player in the pathobiology of multiple myeloma. *BioMed Research International*, **2014**, 2014, 521586	3	40
445	Risk stratification of patients with multiple myeloma prior to autologous stem cell transplant: what is the role of serum ferritin levels?. **2014**, 55, 2419-20		2
444	The potential of miRNAs as biomarkers for multiple myeloma. **2014**, 14, 947-59		19
443	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. **2014**, 99, 232-42		146
442	Can genome array screening replace FISH as a front-line test in multiple myeloma?. **2014**, 53, 676-92		10
441	Novel drug combinations for the management of relapsed/refractory multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14 Suppl, S71-7	2	11
440	Treatment of transplant-eligible patients with multiple myeloma in 2014. **2014**, 28, 815-27		2
439	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 356-69	2	6
438	Znaczenie bortezomibu w leczeniu szpiczaka plazmocytowego u pacjentᵂ z ryzykiem cytogenetycznym. **2014**, 45, 247-257		
437	European perspective on multiple myeloma treatment strategies in 2014. **2014**, 19, 829-44		77
436	Diagnosis and risk stratification in multiple myeloma. **2014**, 28, 791-813		15
435	Controversies in multiple myeloma: to transplant or not?. **2014**, 9, 360-7		2
434	Maintenance therapy for multiple myeloma. **2014**, 28, 839-59		14

415	Plasma cell morphology in multiple myeloma and related disorders. **2015**, 99, 38-62		25
414	Tailoring treatment in myeloma: are there clues from biology?. **2015**, 8, 11-15		0
413	Imaging myeloma and related monoclonal plasma cell disorders using MRI, low-dose whole-body CT and FDG PET/CT. **2015**, 3, 95-109		1
412	Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. **2015**, 50, 658-62		11
411	DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. **2015**, 7, 985-1001		23
410	Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy. **2015**, 33, 496-504		8
409	Defining and treating high-risk multiple myeloma. *Leukemia*, **2015**, 29, 2119-25	10.7	48
408	Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. **2015**, 102, 670-7		4
407	Clinical treatment of newly diagnosed multiple myeloma. **2015**, 8, 595-611		7
406	Clinical characteristics of patients with relapsed multiple myeloma. **2015**, 41, 827-35		26
405	Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. **2015**, 39, 693-9		17
404	SnapShot: Multiple Myeloma. **2015**, 28, 678-678.e1		22
403	Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. **2016**, 7, 47127-47133		5
402	New Targets and New Agents in High-Risk Multiple Myeloma. **2016**, 35, e431-41		11
401	Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. **2016**, 35, e442-8		6
400	Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. **2016**, 35, 210-21		6
399	Towards Stratified Medicine in Plasma Cell Myeloma. **2016**, 17,		6
398	Management of multiple myeloma first relapse after autologous hematopoietic stem cell transplantation. **2016**, 22, 395-405		

397   The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). **2016**, 7, 9666-79   16

396   Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients. **2016**, 95, e3521   16

395   Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients. *American Journal of Hematology*, **2016**, 91, 700-4   7.1   21

394   Cyclin D type does not influence cell cycle response to DNA damage caused by ionizing radiation in multiple myeloma tumours. **2016**, 173, 693-704   5

393   Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma. **2016**, 5, 3051-3058   2

392   Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. *Blood Cancer Journal*, **2016**, 6, e512   7   28

391   Plasma Cell Neoplasms. **2016**,

390   Myeloma: management of the newly diagnosed high-risk patient. **2016**, 2016, 485-494   15

389   Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. **2016**, 14, 150   10

388   Comment on: "Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma". **2016**, 38, 95-6

387   Abstracts for issue YHEM 21 : S1. **2016**, 21, 1-65   1

386   Myeloma Is Not a Single Disease. **2016**, 12, 287-92   9

385   Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. **2016**, 374, 1621-34   684

384   Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. **2016**, 127, 2955-62   463

383   Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. **2016**, 128, 667-79   85

382   Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. **2016**, 22, 1893-1899   19

381   Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma. *American Journal of Hematology*, **2016**, 91, 295-301   7.1   29

380   Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma. **2016**, 9, 63   5

379	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 1129-1134	7.1	42
378	Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 610-615	2	12
377	gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32). **2016**, 12, 1460-1464		5
376	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. **2016**, 17, e328-e346		1155
375	Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. **2016**, 101, 1398-1406		24
374	Controversies in multiple myeloma: Evidence-based update. **2016**, 43, 666-675		6
373	Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation. *International Journal of Laboratory Hematology*, **2016**, 38, 298-307	2.5	4
372	Management of high-risk Myeloma: an evidence-based review of treatment strategies. **2016**, 9, 753-65		2
371	Are maintenance and continuous therapies indicated for every patient with multiple myeloma?. **2016**, 9, 743-51		11
370	Circulating aberrant plasma cells allows risk stratification of patients with myeloma. *American Journal of Hematology*, **2016**, 91, E353-E355	7.1	9
369	Gene signature combinations improve prognostic stratification of multiple myeloma patients. *Leukemia*, **2016**, 30, 1071-8	10.7	43
368	Multiple Myeloma: Treatment is Getting Individualized. **2016**, 32, 3-9		4
367	Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. **2016**, 22, 4039-44		11
366	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 36-42	2	4
365	Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance. **2016**, 57, 1382-8		5
364	Allogeneic stem cell transplantation for multiple myeloma: is there a future?. **2016**, 51, 492-500		39
363	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. **2016**, 387, 1551-1560		581
362	Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma. **2016**, 40, 77-82		22

361   ESRD due to Multiple Myeloma in the United States, 2001-2010. **2016**, 27, 1487-94   24

360   Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. **2016**, 32, 191-205   3

359   Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. *Leukemia*, **2016**, 30, 633-9   10.7   42

358   Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma. *Leukemia*, **2016**, 30, 1197-201   10.7   7

357   Plasma Cell Neoplasms, A Therapeutic Approach. **2016**, 123-141

356   Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. **2016**, 26, 1404-11   24

355   Plasma Cell Neoplasms. **2016**,   1

354   Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. *European Journal of Haematology*, **2016**, 96, 46-54   3.8   23

353   Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. **2017**, 58, 1823-1831   32

352   Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. **2017**, 58, 1-15   10

351   Prognostic Implications of Monosomies in Patients With Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 159-164.e2   2   6

350   Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. **2017**, 281, 365-382   93

349   RGS1 expression is associated with poor prognosis in multiple myeloma. **2017**, 70, 202-207   17

348   Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. **2017**, 176, 908-917   19

347   Prognostic role of circulating exosomal miRNAs in multiple myeloma. **2017**, 129, 2429-2436   161

346   How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. **2017**, 112, 153-170   27

345   Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. **2017**, 177, 254-262   4

344   Nitroxoline shows antimyeloma activity by targeting the TRIM25/p53 axle. **2017**, 28, 376-383   17

343	An Platform for the Prediction of Clinical Response in Multiple Myeloma. **2017**, 77, 3336-3351		34
342	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. **2017**, 23, 3980-3993		51
341	Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma. **2017**, 108, 187-192		8
340	Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases. **2017**, 22, 472-476		8
339	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. **2017**, 102, e22-e25		8
338	Cancer Cytogenetics. **2017**,		4
337	Recurrent Cytogenetic Abnormalities in Multiple Myeloma. **2017**, 1541, 295-302		6
336	Utilizing next-generation sequencing in the management of multiple myeloma. **2017**, 17, 653-663		18
335	Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?. **2017**, 12, 309-316		14
334	Recognition of early mortality in multiple myeloma by a prediction matrix. *American Journal of Hematology*, **2017**, 92, 915-923	7.1	18
333	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. *Leukemia*, **2017**, 31, 1368-1374	10.7	41
332	The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients. **2017**, 40, 616-620		8
331	Detection of complex genomic signatures associated with risk in plasma cell disorders. **2017**, 218-219, 1-9		4
330	Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 825-833	2	5
329	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. **2017**, 130, 2610-2618		69
328	Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall. **2017**, 20, 443-462		23
327	New Treatment Methods in Multiple Myeloma. **2017**, 2, 144-149		0
326	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e600	7	43

307	Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. **2017**, 2017, 6934183		5
306	Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. **2017**, 11, 2399-2408		23
305	Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. *PLoS ONE*, **2017**, 12, e0188988	3.7	19
304	Induction therapy for multiple myeloma: more is not necessarily better!. **2018**, 182, 7-8		1
303	The multiple myelomas - current concepts in cytogenetic classification and therapy. **2018**, 15, 409-421		121
302	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
301	Multiple Myeloma. **2018**, 463-483		
300	Epidemiology and Pathophysiology of Multiple Myeloma. **2018**, 1-15		1
299	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. **2018**, 59, 2305-2317		9
298	Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. **2018**, 7, 831-841		12
297	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. **2018**, 11, 219-237		21
296	Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. **2018**, 124, 1710-1721		24
295	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. **2018**, 121, 74-89		15
294	Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, 225-234	2	4
293	Frail Patients with Newly Diagnosed Multiple Myeloma. **2018**, 539-549		
292	Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e219-e240	2	8
291	Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte-zomib-based therapy for multiple myeloma. **2018**, 22, 43-48		6
290	Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. **2018**, 551-571		

#			
289	Expression of genes MAGE-A3 MAGE-C1, NY-ESO-1 and SSX1 in patients with multiple myeloma at the General Hospital of Mexico. **2018**, 81, 86-92		
288	Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. *Leukemia*, **2018**, 32, 102-110	10.7	108
287	Nucleotide excision repair is a potential therapeutic target in multiple myeloma. *Leukemia*, **2018**, 32, 111-119	10.7	32
286	The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma. **2018**, 59, 710-716		0
285	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2018**, 93, 179-186	7.1	29
284	Personalized Therapy for Multiple Myeloma. **2018**,		1
283	AYA-Myeloma: Real-World, Single-Center Experience Over Last 5 Years. **2018**, 7, 120-124		7
282	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. **2018**, 118, 388-397		20
281	Drug response prediction in high-risk multiple myeloma. **2018**, 644, 80-86		10
280	Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. *Journal of Clinical Oncology*, **2018**, 36, 2012-2016	2.2	1
279	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. **2018**, 379, 1811-1822		268
278	Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data. *BioMed Research International*, **2018**, 2018, 9057823	3	1
277	Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders. **2018**, 228-229, 184-196		8
276	Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma. **2018**, 2018, 4654717		4
275	Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. **2018**, 103, 2079-2087		167
274	Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis. **2018**, 7, 5920-5927		9
273	Multiple myeloma in Korea: risk stratification and initial treatment. **2018**, 53, 183-184		0
272	Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience. **2018**, 38, 196-203		7

271	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. **2018**, 124, 4032-4043		82
270	Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. **2018**, 8, 13522		10
269	Influence of Clonal Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts on Progression and Survival in Multiple Myeloma Patients After Autologous Peripheral Blood Stem Cell Transplantation in Long-term Observation. **2018**, 50, 2202-2211		1
268	Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. **2018**, 2, 1608-1615		18
267	Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. **2018**, 7, 4132-4145		5
266	The role of carfilzomib in treatment of newly diagnosed multiple myeloma. **2018**, 14, 3123-3134		3
265	Potential Clinical Application of Genomics in Multiple Myeloma. **2018**, 19,		5
264	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. **2018**, 24, 2443-2449		8
263	Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis. **2018**, 11, 499-507		10
262	High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma. **2018**, 20, 777-788		5
261	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. **2019**, 60, 442-452		11
260	Recent advances in cytogenetic characterization of multiple myeloma. *International Journal of Laboratory Hematology*, **2019**, 41, 5-14	2.5	23
259	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. *Leukemia*, **2019**, 33, 159-170	10.7	176
258	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. *Blood Cancer Journal*, **2019**, 9, 62	7	17
257	Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. **2019**, 187, 447-458		6
256	Updates and rationale of clinical trials in multiple myeloma. **2019**, 2, e59		
255	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ☐5 years. **2019**, 60, 3536-3543		7
254	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. **2019**, 25, 2134-2142		28

253	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. **2019**, 12, 65		4
252	Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia. *Annals of Hematology*, **2019**, 98, 2569-2578	3	0
251	[Molecular cytogenetic analyses of patients with plasma cell myeloma in Tolna and Baranya counties in Hungary]. **2019**, 160, 944-951		
250	Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-*Annals of Hematology*, **2019**, 98, 2793-2803	3	8
249	High expression of UBE2T predicts poor prognosis and survival in multiple myeloma. **2019**, 26, 347-355		23
248	Epidemiology of Multiple Myeloma. **2019**,		1
247	Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. **2019**, 21, 100159		4
246	A Network Analysis of Multiple Myeloma Related Gene Signatures. **2019**, 11,		16
245	Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma. **2019**, 15, 7-20		9
244	Laboratory assessment of multiple myeloma. **2019**, 89, 1-58		10
243	Pretreatment F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. **2019**, 46, 1325-1333		5
242	High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. **2019**, 133, 1217-1221		45
241	The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. *Leukemia*, **2019**, 33, 863-883	10.7	26
240	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. **2019**, 12, 4		16
239	Prognostic Value of 1q21 Gain in Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e159-e164	2	11
238	Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 183-189.e1	2	8
237	Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e470-e477	2	2
236	STAT3: A Promising Therapeutic Target in Multiple Myeloma. **2019**, 11,		29

235	Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e545-e550	2	4
234	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. *European Journal of Haematology*, **2019**, 103, 107-115	3.8	12
233	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. *Journal of Clinical Oncology*, **2019**, 37, 1657-1665	2.2	51
232	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. **2019**, 125, 2991-3000		47
231	Biology and therapy of multiple myeloma. **2019**, 210, 375-380		29
230	Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. **2019**, 186, 37-44		
229	A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. **2019**, 25, 1312-1319		6
228	Risk of relapse of multiple myeloma following kidney transplantation. **2019**, 12, 216-223		11
227	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. *American Journal of Hematology*, **2019**, 94, 751-756	7.1	6
226	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. *Journal of Clinical Oncology*, **2019**, 37, 1228-1263	2.2	104
225	Risk-Based Therapeutic Strategies. **2019**, 25, 54-58		2
224	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. *Lancet Haematology,the*, **2019**, 6, e154-e166	14.6	44
223	Evaluating the role of Tregs in the progression of multiple myeloma. **2019**, 60, 2134-2142		10
222	Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. **2019**, 41, 477-493.e7		7
221	Physicians, paraproteins and progress: diagnosis and management of myeloma. **2019**, 80, 91-98		4
220	Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics. **2019**,		1
219	Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. **2019**, 3, 4202-4214		35
218	Application of Genomics to Clinical Practice in Haematological Malignancy. **2019**, 7, 236-252		

217	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. *Blood Cancer Journal*, **2019**, 9, 101	7	22
216	Revised International Staging System Is Predictive and Prognostic for Early Relapse (. **2019**, 25, 683-688		12
215	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430	7.1	5
214	Bone marrow transplant and pediatric multiple myeloma. **2019**, 66, e27528		2
213	Cancer Stem Cells in Multiple Myeloma and the Development of Novel Therapeutic Strategies. **2019**, 121-137		1
212	Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. **2019**, 25, 474-479		5
211	Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology. **2019**, 37, 727-737		3
210	Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. *European Journal of Haematology*, **2019**, 102, 182-190	3.8	16
209	Levels of CD8+ tumor infiltrating lymphocytes correlate with disease burden in bone marrow of therapy Naïve multiple myeloma patients. **2019**, 40, 174-175		
208	Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy. **2019**, 145, 561-571		14
207	Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. **2019**, 104, 370-379		40
206	Multiple Myeloma of the Young - a Single Center Experience Highlights Future Directions. **2020**, 26, 419-424		1
205	Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma. **2020**, 33, 188-195		1
204	Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. **2020**, 111, 65-74		8
203	Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. **2020**, 61, 37-46		5
202	Prognosis value of RBBP8 expression in plasma cell myeloma. **2020**, 27, 22-29		4
201	Risk Stratification in Multiple Myeloma in Indian Settings. **2020**, 36, 464-472		1
200	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. **2020**, 26, 665-671		7

199	1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib. **2020**, 61, 1201-1210		9
198	Healthcare reality of the treatment of the high-risk multiple myeloma in Spain. **2020**, 154, 315-319		
197	Clinical impact of the CONUT score in patients with multiple myeloma. *Annals of Hematology*, **2020**, 99, 113-119	3	18
196	Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China. **2020**, 14, 327-334		1
195	High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients. *Frontiers in Oncology*, **2020**, 10, 563666	5.3	4
194	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. **2020**, 191, 442-452		2
193	Primary refractory multiple myeloma: a real-world experience with 85 cases. **2020**, 61, 2868-2875		3
192	Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant. **2020**,		78
191	A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. **2020**, 11,		1
190	Education level as a predictor of survival in patients with multiple myeloma. **2020**, 20, 737		2
189	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 108	7	20
188	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. **2020**, 21, 1630-1642		110
187	Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China. **2020**, 9, 7819-7829		4
186	The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. *American Journal of Hematology*, **2020**, 95, 1562-1571	7.1	7
185	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. *Blood Cancer Journal*, **2020**, 10, 91	7	36
184	Deep sequencing as an approach to understanding the complexity and improving the treatment of multiple myeloma. **2020**, 5, 363-370		
183	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. **2020**, 13, 115		15
182	Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma Cells. **2020**, 40, 389-405		5

181	Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. *Leukemia*, **2021**, 35, 2043-2053	10.7	10
180	Plasma cell leukemia characterized by EDTA-dependent plasma cell agglutination: a case report. **2020**, 9, 2330-2332		1
179	IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. *European Journal of Haematology*, **2020**, 105, 326-334	3.8	2
178	Cytogenetic abnormalities in patients with newly diagnosed multiple myeloma as a secondary primary malignancy: a retrospective study. **2020**, 25, 176-180		1
177	Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 704-711	2	1
176	Healthcare reality of the treatment of the high-risk multiple myeloma in Spain. **2020**, 154, 315-319		
175	The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides. **2020**, 61, 2351-2364		5
174	Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. *Hematological Oncology*, **2020**, 38, 584-588	1.3	4
173	PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. *BioMed Research International*, **2020**, 2020, 4286101	3	2
172	Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma. **2020**, 9, 5819-5826		7
171	Abnormal PTBP1 Expression Sustains the Disease Progression of Multiple Myeloma. **2020**, 2020, 4013658		1
170	Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. **2020**, 12,		1
169	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. *Blood Cancer Journal*, **2020**, 10, 14	7	3
168	Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma. **2020**, 125, 110005		6
167	Multiple Myeloma: Available Therapies and Causes of Drug Resistance. **2020**, 12,		62
166	Current Treatment Strategies for Multiple Myeloma. **2020**, 16, 5-14		13
165	Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. **2020**, 9, 1694-1702		1
164	Genomic profiling of multiple myeloma: New insights and modern technologies. **2020**, 33, 101153		1

163	Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. **2020**, 12,		15
162	Drug Targeting of Genomic Instability in Multiple Myeloma. **2020**, 11, 228		6
161	Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance. **2020**, 10, 5991		17
160	PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma. **2020**, 12,		19
159	Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. **2020**, 11, 501		41
158	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. *Blood Cancer Journal*, **2020**, 10, 40	7	7
157	Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect MM Registry. **2021**, 193, 93-100		2
156	Risk factors in multiple myeloma: is it time for a revision?. **2021**, 137, 16-19		11
155	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. *Leukemia*, **2021**, 35, 1732-1744	10.7	3
154	del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. **2021**, 137, 1192-1195		19
153	Melphalan 200 mg/m does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients. **2021**, 56, 1209-1212		2
152	Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma. **2021**, 56, 1116-1125		2
151	Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, e220-e226[2]		3
150	-. **2021**, 14, 156-166		2
149	Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015. **2021**, 29, 4501-4511		
148	Prognostic and Predictive Factors in Newly Diagnosed Multiple Myeloma Patients with Early Mortality with Prediction Matrix and Three and Five-Year Overall Survival.		
147	Roles of miRNA dysregulation in the pathogenesis of multiple myeloma. **2021**, 28, 1256-1268		9
146	Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study. *Therapeutic Advances in Hematology*, **2021**, 12, 20406207211035272	5.7	2

No.	Title	IF	Cites
145	Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management. **2021**, 107, NP37-NP40		3
144	Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. *Cells*, **2021**, 10,	7.9	8
143	The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma. *Annals of Hematology*, **2021**, 100, 1251-1260	3	2
142	Deletion 17p: a matter of size and number?. **2021**, 137, 1135-1136		0
141	MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. **2021**, 11, e046225		5
140	Immunological Prognostic Factors in Multiple Myeloma. **2021**, 22,		4
139	Targeting Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14). **2021**, 27, 606567		
138	miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition. **2021**, 148, 3071-3085		3
137	Oligosecretory multiple myeloma: a devastating presentation of a difficult diagnosis. **2021**, 14,		0
136	Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation. **2021**, 14, 2349-2361		0
135	Chromosome 1q21 abnormalities in multiple myeloma. *Blood Cancer Journal*, **2021**, 11, 83	7	16
134	CAR T-cell therapy in multiple myeloma: more room for improvement. *Blood Cancer Journal*, **2021**, 11, 84	7	27
133	MMRFBiolinks: an R-package for integrating and analyzing MMRF-CoMMpass data. **2021**, 22,		2
132	Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center. **2021**, 100, e25834		
131	The Evaluation of the Multiple Myeloma Pathological Osseous Tissue of Microarchitecture. **2021**, 17, 513-516		
130	Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data. *Leukemia*, **2021**, 35, 2924-2935	10.7	6
129	Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. *Leukemia*, **2021**, 35, 3600-3603	10.7	2
128	Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets. *Cells*, **2021**, 10,	7.9	7

127	Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma. **2021**, 60, 668-677		
126	Machine learning predicts treatment sensitivity in multiple myeloma based on molecular and clinical information coupled with drug response. *PLoS ONE*, **2021**, 16, e0254596	3.7	2
125	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 451-460.e2	2	2
124	Clinical Proteomics of Biofluids in Haematological Malignancies. **2021**, 22,		1
123	Knowing the unknowns in high risk multiple myeloma. **2021**, 51, 100887		1
122	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. **2021**, 8, 712070		2
121	Hyperdiploid Multiple Myeloma with Novel Complex Structural Chromosome Abnormalities Associated with Poor Prognosis : A Rare Case Report.. **2021**, 15, 199-205		
120	Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project. **2021**, 2, 809		
119	Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways.		
118	Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma - The Oregon Health and Science University Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**,	2	
117	RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma. **2021**, 11,		0
116	Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. **2021**, 17, 4849-4860		2
115	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). *Blood Cancer Journal*, **2021**, 11, 150	7	1
114	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. **2021**, 29, 100444		1
113	Myeloma and Related Conditions. **2021**, 274-305		
112	Multiple Myeloma. **2020**, 61-95		1
111	Current concepts and future directions for hemato-oncologic diagnostics. **2020**, 151, 102977		6
110	Current status of art mobilization in Myeloma. **2017**, 56, 850-853		6

109	Dissecting racial disparities in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 19	7	34
108	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. **2017**, 58, 55-71		4
107	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. **2020**, 4, 2163-2171		13
106	Plasma Cell Myeloma with an Aggressive Clinical Course and Anaplastic Morphology in a 22-Year-Old Patient: A Case Report and Review of Literature. **2020**, 21, e920489		2
105	Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. *PLoS ONE*, **2016**, 11, e0147381	3.7	13
104	How I treat elderly patients with plasma cell dyscrasias. **2018**, 10, 4248-4268		5
103	Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma. **2017**, 8, 69408-69421		9
102	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. **2017**, 8, 56338-56350		25
101	Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. **2017**, 8, 112685-112696		24
100	Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. **2015**, 6, 9434-44		8
99	KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. **2015**, 6, 14814-31		51
98	Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population. **2020**, 15, 182-188		1
97	[Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients]. **2018**, 39, 408-413		1
96	[Expression of CD45 in newly diagnosed multiple myeloma and the relationship with prognosis]. **2019**, 40, 744-749		2
95	miR-451a suppression of IL-6R can inhibit proliferation and increase apoptosis through the JAK2/STAT3 pathway in multiple myeloma. **2020**, 20, 339		2
94	Recent advances in multiple myeloma: a Korean perspective. **2016**, 31, 820-34		15
93	Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. **2017**, 32, 711-721		11
92	Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. **2016**, 31, 809-19		6

91	Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. **2019**, 34, 1333-1346		1
90	Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China. **2017**, 130, 130-134		5
89	Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. **2015**, 159, 288-93		8
88	Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis. *Frontiers in Oncology*, **2021**, 11, 757664	5.3	0
87	The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells. *International Journal of Laboratory Hematology*, **2021**, 44, 157	2.5	1
86	Mature B- and T-cell neoplasms and Hodgkin lymphoma. 252-331		1
85	Cytogenetics of Plasma Cell Neoplasms. **2016**, 79-97		
84	Treatment of t(4;14) and del(17p) in Multiple Myeloma. **2018**, 59-76		
83	Risk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma. **2018**, 15-36		
82	Personalizing MM Treatment: Gaps in Current Knowledge. **2018**, 169-178		
81	Plasma Cell Myeloma. **2018**, 806-817		
80	Evolution of Anti-Cancer Treatment and its Impact on Surrogate Prognostic Factors in Multiple Myeloma. *Klinicheskaya Onkogematologiya/Clinical Oncohematology*, **2018**, 11, 175-181	0.3	1
79	Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma. **2019**, 15, 87		2
78	Amplification of the MYC gene in immunoglobulin light chain (AL) amyloidosis. **2019**, 22, 54-62		
77	Patient Similarity Network of Multiple Myeloma Identifies Patient Sub-groups with Distinct Genetic and Clinical Features.		2
76	Spine Metastasis in Elderly: Encouraging Results for Better Survival. **2021**, 46, 751-759		0
75	Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (2nd relapse) refractory myeloma: a multicenter real world UK experience. **2021**, 62, 1396-1404		1
74	, , and mutations in plasma cell myeloma at a single Korean institute. **2020**, 55, 159-168		

73	[Clinical characteristics and survival of newly diagnosed multiple myeloma patients under 40 years old from single center and literature review]. **2015**, 36, 933-6		
72	[Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities]. **2019**, 40, 644-649		0
71	[Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy]. **2019**, 40, 693-696		0
70	[Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation]. **2018**, 39, 496-500		
69	A centromere-associated gene score for rapid determination of risk in multiple myeloma. **2020**, 12, 2425-2438		2
68	[Efficacy and prognosis of PAD combination therapy for fifty-six previously untreated patients with multiple myeloma]. **2016**, 37, 520-2		
67	[Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study]. **2020**, 41, 10-15		
66	Identification of metabolic biomarkers to predict treatment outcome and disease progression in multiple myeloma. **2020**, 10, 3935-3946		
65	[A predictive model based on risk factors for early mortality in patients with newly diagnosed multiple myeloma]. **2021**, 42, 666-672		
64	Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma. 1		
63	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. **2021**, 7, eabg9551		10
62	SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**,		2
61	Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. *Hematological Oncology*, **2021**,		1.3
60	Multiples Myelom: Die Therapie ist im Fluss.		
59	New Progress in Multiple Myeloma Targeted Therapy. **2021**, 11, 5144-5150		
58	Gene expression profiling as a prognostic tool in multiple myeloma.. **2021**, 4, 1008-1018		0
57	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.. *Leukemia*, **2022**,	10.7	0
56	Genomic characterization of functional high-risk multiple myeloma patients.. *Blood Cancer Journal*, **2022**, 12, 24	7	2

55	The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?. *Clinical Lymphoma, Myeloma and Leukemia*, **2022**,	2	0
54	CD38 - Negative Anaplastic Plasma Cell Myeloma: A Rare Case Report.. **2022**, 14, e20909		
53	Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.. **2022**, 12, 1715-1729		0
52	A Novel Prognostic Model Based on Nine-Targeted Therapeutic Response Relevant Secreted Protein Genes (Trspgs) from Single-Cell Rna Sequencing in Multiple Myeloma.		
51	Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 15	7	1
50	A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21	7	4
49	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma.. *Cell Reports Medicine*, **2022**, 3, 100508	18	0
48	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.. *Frontiers in Oncology*, **2022**, 12, 820768	5.3	0
47	Comparison of clinical and laboratory characteristics of nonsecretory multiple myeloma and secretory multiple myeloma in a tertiary care hospital.. *International Journal of Laboratory Hematology*, **2022**,	2.5	
46	Bone metabolism parameters and their relation to cytogenetics in multiple myeloma.. *European Journal of Haematology*, **2022**,	3.8	
45	Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.. *Frontiers in Oncology*, **2022**, 12, 830922	5.3	2
44	Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma.. *Cells*, **2022**, 11,	7.9	0
43	What Is Genomic High-Risk Myeloma?. *Hemato*, **2022**, 3, 287-297	0.2	
42	Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study.. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**,	2	
41	The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.. *Therapeutic Advances in Hematology*, **2022**, 13, 20406207221082043	5.7	0
40	Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma.. *BioMed Research International*, **2022**, 2022, 3307873	3	0
39	Data_Sheet_1.PDF. **2020**,		
38	Overexpression of the Energy Metabolism Transcriptome within Clonal Plasma Cells is Associated with the Pathogenesis and Outcomes of Patients with Multiple Myeloma.. *American Journal of Hematology*, **2022**,	7.1	0

37	Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience.. *American Journal of Hematology*, **2022**,	7.1	1
36	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.. *Lancet Haematology,the*, **2022**,	14.6	3
35	Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.. *PLoS ONE*, **2022**, 17, e0267979	3.7	0
34	Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk.. *Annals of Hematology*, **2022**,	3	
33	Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. *Hematological Oncology*,	1.3	1
32	High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. *Blood Cancer Journal*, **2022**, 12,	7	3
31	High Dose (Conditioning) Regimens used prior to Autologous Stem Cell Transplantation in Multiple Myeloma. *Transplantation and Cellular Therapy*, **2022**,		1
30	Stratification of Patients with Multiple Myeloma: State-of-the-Art and Prospects. *Klinicheskaya Onkogematologiya/Clinical Oncohematology*, **2022**, 15, 259-270	0.3	
29	Machine Learning‑Based Overall Survival Prediction of Elderly Patients With Multiple Myeloma From Multicentre Real-Life Data. *Frontiers in Oncology*, 12,	5.3	
28	Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?. *Journal of Clinical Oncology*,	2.2	0
27	Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience. *Internal Medicine Journal*,	1.6	
26	Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials. *Frontiers in Oncology*, 12,	5.3	
25	Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms.		1
24	Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.		
23	Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.		0
22	Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. 13,		0
21	Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens. 12,		0
20	The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients. 12,		1

19	Clinical Significance of Circulating Clonal Plasma Cells Detected by a Novel Microfluidic Chip in Multiple Myeloma. **2022**, 18, 1630-1639	0
18	Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. 12,	0
17	Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.	0
16	Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. **2022**, 12, e063037	0
15	Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma.	0
14	Clinical, economical and ethical aspects assessing therapy outcomes in patients with multiple myelomas of high cytogenetic risk. **2022**,	0
13	High or low? Assessing disease risk in multiple myeloma. **2022**, 2022, 349-355	0
12	Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment.	0
11	CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14). 12,	0
10	Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies.	0
9	Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma. **2023**,	0
8	Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. 107815522211509	0
7	Obesity and myeloma: Clinical and mechanistic contributions to disease progression. 14,	0
6	Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.	0
5	Machine Learning Model Based on Optimized Radiomics Feature from 18F-FDG-PET/CT and Clinical Characteristics Predicts Prognosis of Multiple Myeloma: A Preliminary Study. **2023**, 12, 2280	0
4	Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors. **2023**, 11, 964	0
3	A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma. **2023**, 24, 6683	0
2	Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma. 11,	0

1   Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma.   0

27